Background {#Sec1}
==========

Autoimmune encephalitis (AE), which is characterized by the subacute (days to weeks) development of seizures, recent memory loss, mental confusion and psychiatric symptoms due to antibodies against neuronal cell surface and synaptic proteins, is newly recognized autoimmune disorders involved in synaptic transmission and neuronal excitability \[[@CR1]\]. Although thymoma or thymic carcinoma has been reported to be associated with AE, the most common targets are LGI1, Caspr2 and γ-aminobutyric acid (GABA)- A type receptor antibody encephalitis \[[@CR2]--[@CR5]\]. Thymoma-associated encephalitis associated with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), one of neuronal surface autoantigens, is rare \[[@CR6]\]. In this report, we describe a female thymomatous myasthenia gravis (MG) patient with AMPAR encephalitis onset after a complete thymectomy without recurrence of the thymoma.

Case presentation {#Sec2}
=================

A 50-year-old woman presenting with subacute onset of memory loss and behavioral changes lasting for one month was admitted to our hospital on July 9, 2018. On examination, she was confused and apathetic, disoriented to time and space with impaired memory and executive dysfunction, slurred speech with partly comprehensive aphasia, and urinary and fecal incontinence when she was admitted to our hospital. She was poorly collaborative in Mini-Mental State Examination (MMSE). No localized symptoms or signs were observed.

Two years ago, this patient presented at age 48 with right ptosis. She was diagnosed with MG based on positive AChR Ab (titre \> 20 nmol/L) and a neostigmine test, as well as a decrement of 15% in low frequency (3 Hz) repetitive nerve stimulation on orbicularis oculi muscles, trapeziuses and deltoid muscles. A computerized tomography (CT) chest showed a thymoma (3.1 cm × 1.9 cm), which was resected on August 22, 2016 (Fig. [1](#Fig1){ref-type="fig"}a). Histological examination showed WHO type B2: Kpan(+++), CK19(+++), CD30(+++), CD20(−), CD3(−), CD5(+), TdT(+), and Ki67(+, 90%). Whole-body bone scans by emission computed tomography were normal. Space-occupying lesions were not found in the liver, kidneys or subclavian area investigated with B-ultrasound. For the next two years, the patient's symptoms were well-controlled with pyridostigmine treatment.Fig. 1Chest CT showed a 3.1 cm × 1.9 cm thymoma on August 3, 2016 (**a**) and was normal without thymoma recurrence after thymectomy on July 11, 2018 (**b**)

Routine serum analyses were within the normal range, including thyroid hormones and associated antibodies, anti-nuclear antibody, and anti-dsDNA. Polymerase chain reaction (PCR) for herpes simplex virus, cytomegalovirus, influenza virus, enterovirus, and measles virus in serum were also negative. Cell count, protein, glucose and chloride were normal in the cerebrospinal fluid (CSF). CSF and serum were negative for oligoclonal bands. Antibodies against cell surface or synaptic proteins were assessed in serum and CSF obtained before immunotherapy using transfected HEK-293 cells by the indirect immunofluorescence method (Kindstar Global, Wu Han, China) showed high levels of serum (1:1000) and CSF (1:32) antibodies against the AMPAR GluR2 (AMPAR2, Fig. [2](#Fig2){ref-type="fig"}b and d). A wide range of abnormalities in 6--8 Hz low to middle slow waves was found by electroencephalographs (EEGs). Brain magnetic resonance images (MRI) identified high-intensity signals on fluid-attenuated inversion recovery (Flair) in both the medial temporal lobe and hippocampus on June 25, 2018 (Fig. [3](#Fig3){ref-type="fig"}). Antibodies against α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) GluR1, N-methyl-D-aspartate receptor, GABA B type receptor, leucine-rich glioma inactivated protein 1 (LGI1) and Caspr2 were negative. The chest CT was normal without thymoma recurrence after thymectomy on July 11, 2018 (Fig. [1](#Fig1){ref-type="fig"}b). Ultrasounds of the liver, pancreas, spleen, kidney, bladder, ovary and uterus, as well as serological tumor markers, were also normal and did not reveal a neoplasm. Anti-AMPAR2 encephalitis was thus diagnosed. Intravenous methylprednisolone (1 g/day for 3 days and 500 mg/day for 3 days) followed by oral prednisolone (1 mg/kg/day) was administered with slow tapering. The patient's symptoms did not have significant remission, and azathioprine (50 mg twice a day) was applied when she was discharged on July 20, 2018. A neuropsychological exam showed memory deficit, calculative and comprehensive dysfunction, lack of motivation and social emotion and urinary incontinence.Fig. 2Neuroimmunological investigations showed high levels of serum (1:1000, **b**) and CSF (1:32, **d**) antibodies against the AMPAR GluR2. **a** and **c** were serum and CSF negative control respectivelyFig. 3Brain MRI performed on June 25, 2018 identified high-intensity signals on fluid-attenuated inversion recovery in both the medial temporal lobe and hippocampus

The patient had voluntary urinary control, and the initial MRI lesions resolved in 16 days (July 11, 2018). The patient only had mild long-time memory deficits and a good recovery with an MMSE score of 24 at follow-up on September 13, 2018.

Discussion {#Sec3}
==========

AMPAR is a subtype of glutamate receptor that mediates most of the fast excitatory neurotransmission in the brain. The majority of AMPAR are tetramers composed of GluR1, 2, 3 or 4 subunits. A high level of GluR1/2 and GluR2/3 receptors is found in the synaptic CA3-CA1 areas of the hippocampus followed by the subiculum, cerebellum, caudate-putamen, and cerebral cortex \[[@CR7]\].

The thymus is a central organ for the development of the immune system, particularly for the selection of T cells with appropriate self-tolerance \[[@CR8]\]. It is not surprising that thymoma is considered to be a possible initiator for most paraneoplastic neurological disease, such as AE \[[@CR8]\]. In 2009, Lai \[[@CR7]\] first reported three patients with anti-AMPAR encephalitis, and thymoma were identified among 109 cases of limbic encephalitis. To date, eleven cases of thymoma-associated anti-AMPAR2 encephalitis have been described in six publications (Table [1](#Tab1){ref-type="table"}) \[[@CR6], [@CR7], [@CR9]--[@CR12]\]. In most cases, thymoma was detected in oncological screening with the first episode of encephalitis, though a malignant thymoma treated with radiotherapy and chemotherapy six years prior to encephalitis was found in one case \[[@CR9]\]. Our case was unique in that the patient initiated with the symptom of myasthenia gravis and thymoma two years prior to AE, and a complete thymectomy was performed before AE onset without recurrence of the thymoma when AE occurred. Recently, a patient with anti-AMPAR encephalitis who was reported to be in remission for 34 months showed clinical relapse three months after the detection of recurrent thymoma \[[@CR11]\]. Hor et al. reported a case of thymoma-associated myasthenia gravis and LGI1-encephalitis with nephrotic syndrome after thymectomy \[[@CR13]\]. Our case raises the questions of whether the autoantigens could be expressed by the thymus after thymectomy, and how these autoantigens from thymic tumors could trigger immune disorders. It is probable that these autoantigens were expressed by the thymus at an early stage before thymectomy and existed in the central nervous system or blood circulatory system and that AE was triggered by these autoantigens due to virus infection or over-fatigue.Table 1Relation of thymoma and outcome in patients with anti-AMPAR encephalitisCasesex/ ageTumorTime from symptoms of AE to tumor diagnosisOther autoimmune or antibodiesTreatmentOutcomeReference1F/44Thymic carcinomaConcurrent with first episode of encephalitisANA, dsDNA, cardiolipin antibodiesTumor removal. At presentation and relapse: IVIg, corticosteroids. Chronic treatment with azathioprine.First episode: returned to baseline. Subsequent relapsing: memory deficit. Residual short-term memory deficit after 3rd relapse.Lai et al. 20092M/38Malignant thymomaConcurrent with relapse of encephalitisGAD antibodiesTumor removal, radiation therapy, corticosteroids, plasma exchange, IVIgFirst episode: returned to baseline. Mild residual memory deficit after relapse; steroid dependant muscle spasms and rigidity.Lai et al. 20093F/44ThymomaConcurrent with first episode of encephalitisCV2/CRMP5 antibodiesN/AUnexpected death due to cardiorespiratory arrest.Lai et al. 20094F/60Malignant thymomaSix years before first episode of encephalitis with residual thymoma without evidence of relapse.NoneRadiotherapy and chemotherapy six years before AE without thymectomy. At presentation: corticosteroidsComplete recoveryGraus et al. 20105F/47Thymoma (WHO type B1)Concurrent with first episode of encephalitisanti-AchR and titin antibodiesCorticosteroid at first episode. Corticosteroid, azathioprine and tumor removal when relapse.First episode: short term memory deficit, severe anomic aphasia, executive dysfunction.Mild anomic aphasia and bulbar symptoms when relapse.Li et al. 2015662/MMalignant thymomaConcurrent with first episode of encephalitisNoneTumor removal, corticosteroid, IVIgFull treatment responseHöftberger et al. 2015723/MThymomaConcurrent with first episode of encephalitisNoneTumor removal, IVIg, corticosteroid, rituximabPartial treatment responseHöftberger et al. 2015853/FMalignant thymomaConcurrent with first episode of encephalitisCRMP5Tumor removal, chemotherapy, radiotherapy, corticosteroid, IVIgNo treatment responseHöftberger et al. 2015971/MThymic carcinoidConcurrent with first episode of encephalitisNMDARTumor removal, corticosteroid, plasma exchangeFull treatment responseHöftberger et al. 20151021/MThymic carcinoidConcurrent with first episode of encephalitisNoneTumor removal, chemotherapy, radiotherapy, corticosteroid, IVIgMild deficits in working memory persisted at 18 months after disease onset.Joubert et al. 201511F/34Thymoma (WHO type B3)Concurrent with first episode of encephalitis; Recurrence with clinical relapseNoneCorticosteroid and tumor removal at first episode.Corticosteroid and resection of the recurrent tumor after relapse.First episode: depressive symptoms.Memory deficits after relapse.Omi et al. 201812F/50Thymoma (WHO type B2)2 years before first episode of encephalitisanti-AchR antibodiesTumor removal 2 years before AE. Corticosteroid and azathioprine.First episode: returned to baseline.Huang et al.Abbreviations: *N/A* not applicable, *IVIg* intravenous immunoglobulin

Fourteen cases in 22 patients with anti-AMPAR encephalitis had tumors, such as lung cancer, thymoma, breast cancer, or ovarian teratoma, indicating that paraneoplastic autoimmunity plays a key role in the pathogenic mechanisms of anti-AMPAR encephalitis \[[@CR10], [@CR14]\]. Our case is more likely paraneoplastic autoimmune encephalitis even if encephalitis emerged 2 years after thymoma diagnosis.

Anti-AMPAR encephalitis has been reported to be associated with other autoimmune antibodies, such as antibodies against ANA, dsDNA, cardiolipin, glutamic acid decarboxylase (GAD), CV2/CRMP5 and AChR \[[@CR5], [@CR6]\]. AChR Ab is also positive in our patient; however, the immune relationships between these antibodies and AMPAR Ab has not been thoroughly elucidated to date.

Based on the clinical outcome of our patient and review of the published literature, tumor removal with or without chemotherapy and radiotherapy may be applied to anti-AMPAR encephalitis with thymic tumors, and immunotherapy including corticosteroids, IVIg and plasma exchange during presentation or relapse and chronic treatment with rituximab or azathioprine may prevent relapse and improve outcomes. In patients with anti-AMPAR encephalitis, oncological screening is mandatory with a particular focus on the thymus, lung and breast \[[@CR12]\].

There are several limitations to our study. A more intense oncological screening and long-term follow-up is needed to determine whether the patient has other tumors or metastatic tumors in addition to thymoma.

In conclusion, we presented a case in which a thymectomy was applied in a myasthenia gravis patient with thymoma two years prior to the onset of anti-AMPAR2 encephalitis. This case highlights the complexity of autoimmune encephalitis associated with thymoma.
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